The Effect of Clinical Decision Support System on the Success of Respirative Syncytial Virus (RSV) Prophylaxis

Efect of Clinical Decision Support on Prophylaxis

Abstract

Aim: It was aimed to examine the increase in the rate of respiratory syncytial virus (RSV) prophylaxis through a clinical decision support system (CDSS) added to the hospital information management system (HIS) and to determine the increase rate before and after CDSS.

Methods: In October 2023, a CDSS was defined in HIS following the RSV prophylaxis indication protocol. To measure the effect of CDSS, and to determine the patients who need to receive RSV prophylaxis between 2021 and 2024, the drug reports registered on HIS are determined retrospectively with the code "B97.4-Respiratory syncytial virus, the causative agent of diseases classified in other sections" and the number of patients who started prophylaxis recorded throughout three consecutive seasons.

Results: 31 patients between 2021-2022, 42 patients between 2022-2023 and 68 patients between 2023-2024 were immunized by issuing a report for RSV prophylaxis. According to these data, while there was a 35% increase in the prophylaxis rate before CDSS compared to the previous season, this increased rate after CDSS was found to be 61%.

Recommendations: Systemic alerts added to hospital systems create significant differences in the treatment and follow-up of patients, considering the busy workload of healthcare professionals.